AREDS 2 stands for Age-Related Eye Disease Study 2 and it is a multi-center, randomized trial designed study that was announced in late 2006 to assess the effects of oral supplementation of high dose of Carotenoids and/or omega-3 fatty acids on the progression to advanced Dry Macular Degeneration.
This study will also investigate the original AREDS formulation by comparing low zinc (25 mg) against high zinc (80 mg).
Another goal of the study is to investigate new forms of the AREDS nutritional supplement with low zinc and/or no beta-carotene against the original AREDS supplement in decreasing the incidence of progression to advanced macular degeneration.
Although there is no direct, clear connection between vision and Omega 3 Fatty Acids in people without eye diseases, they are needed by the retina. They can also protect the retina. Continuing studies will give more answers about this subject so that people of all ages will know how much to take.
Who is a good candidate for AREDS 2 study:
Patients who have:
1- Bilateral large drusens.
2- Large drusens in one eye and advanced AMD in the other.
What are the supplements in this study:
In this study the patients will be given for a total six years:
1- Original AREDS formulation.
2- High dose of Carotenoids: Lutein and Zeaxanthin.
Investigators noted that patients in the original AREDS formulation were less likely to progress into advanced AMD when they are on high dietary levels of these two Carotenoids.
3- Long chain omega-3 fatty acid such as DHA and EPA.
Those patients who consumed at least two servings of fish a week in the original study were less likely to progress to advanced AMD. Omega-3 fatty acids can be found naturally in fish oils.